Anti-GD2 immunotherapy for neuroblastoma.
Anti-GD2 immunotherapy for neuroblastoma.
复制标题
DOI：
10.1080/14737140.2017.1364995
复制
发表时间：
2017-10
影响因子：
3.3
通讯作者：
Modak S
中科院分区：
文献类型：
--
作者：
Sait S;Modak S
目前高危神经母细胞瘤（HR-NB）的治疗方法包括高剂量化疗、手术和放疗;与长期和短期毒性相关的干预措施。有效的免疫疗法通过减少对细胞毒性剂的暴露而具有改善生存和生活质量的特别希望。GD 2是一种表面糖脂，是免疫治疗最常见的靶点。我们回顾了目前临床上用于神经母细胞瘤的抗GD 2免疫疗法的现状以及临床前开发中的新型GD 2靶向策略。抗GD 2单克隆抗体与首次缓解患者的生存率提高相关，并且越来越多地用于化疗难治性和复发性神经母细胞瘤。随着蛋白质工程技术变得越来越容易获得，正在测试新的抗体构建体。GD 2也被自然杀伤细胞和T细胞靶向。抗GD 2疫苗可引发主动免疫。目前可用的和即将出现的免疫治疗方法的合理组合，以及它们与传统多模式治疗的整合，将需要进一步的研究来优化它们对HR-NB的使用。
Current therapeutic approaches for high-risk neuroblastoma (HR-NB) include high-dose chemotherapy, surgery and radiotherapy; interventions that are associated with long and short-term toxicities. Effective immunotherapy holds particular promise for improving survival and quality of life by reducing exposure to cytotoxic agents. GD2, a surface glycolipid is the most common target for immunotherapy. We review the status of anti-GD2 immunotherapies currently in clinical use for neuroblastomas and novel GD2-targeted strategies in preclinical development. Anti-GD2 monoclonal antibodies are associated with improved survival in patients in their first remission and are increasingly being used for chemorefractory and relapsed neuroblastoma. As protein engineering technology has become more accessible, newer antibody constructs are being tested. GD2 is also being targeted by natural killer cells and T-cells. Active immunity can be elicited by anti-GD2 vaccines. The rational combination of currently available and soon-to-emerge immunotherapeutic approaches, and their integration into conventional multimodality therapies will require further investigation to optimize their use for HR-NB.
登录
查看更多内容
影响因子：
45.3
作者：
Cheung, Nai-Kong V.;Ostrovnaya, Irina;Cheung, Irene Y.
通讯作者：
Cheung, Irene Y.
影响因子：
45.3
作者：
Cheung, Nai-Kong V.;Cheung, Irene Y.;Modak, Shakeel
通讯作者：
Modak, Shakeel
影响因子：
8.4
作者：
Baxevanis, CN;Tsavaris, NB;Papamichail, M
通讯作者：
Papamichail, M
影响因子：
7.2
作者：
Cheng M;Santich BH;Xu H;Ahmed M;Huse M;Cheung NK
通讯作者：
Cheung NK
影响因子：
6.4
作者：
Cheung NK;Cheung IY;Kramer K;Modak S;Kuk D;Pandit-Taskar N;Chamberlain E;Ostrovnaya I;Kushner BH
通讯作者：
Kushner BH